View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2012	Jun. 30, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	CHEMBIO DIAGNOSTICS, INC.
Entity Central Index Key	0001092662
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$ 28,500,000
Entity Common Stock, Shares Outstanding	8,086,114
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2012

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2012	Dec. 31, 2011
CURRENT ASSETS:
Cash and cash equivalents	$ 2,951,859	$ 3,010,954
Accounts receivable, net of allowance for doubtful accounts of $58,000 and $30,000 at December 31, 2012 and 2011, respectively	4,821,357	2,998,449
Inventories	2,488,071	2,300,286
Prepaid expenses and other current assets	747,463	681,893
TOTAL CURRENT ASSETS	11,008,750	8,991,582
FIXED ASSETS, net of accumulated depreciation	1,427,646	1,062,276
OTHER ASSETS:
Deferred tax asset, net of valuation allowance	4,233,194	4,749,622
License agreements, net of current portion	400,000	500,000
Deposits on manufacturing equipment	223,584	139,790
Deposits and other assets	41,976	42,474
TOTAL ASSETS	17,335,150	15,485,744
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	3,303,923	2,789,500
Current portion of loans payable	51,236	53,550
Customer deposits	23,224	0
Current portion of obligations under capital leases	0	14,576
TOTAL CURRENT LIABILITIES	3,378,383	2,857,626
OTHER LIABILITIES:
Loans payable - net of current portion	82,247	133,484
TOTAL LIABILITIES	3,460,630	2,991,110
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Preferred stock - 10,000,000 shares authorized, none outstanding	0	0
Common stock - $.01 par value; 100,000,000 shares authorized, 8,036,232 and 7,921,021 shares issued and outstanding for 2012 and 2011, respectively	80,362	79,210
Additional paid-in capital	41,116,149	40,678,696
Accumulated deficit	(27,321,991)	(28,263,272)
TOTAL STOCKHOLDERS' EQUITY	13,874,520	12,494,634
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 17,335,150	$ 15,485,744

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
CURRENT ASSETS:
Accounts receivable, allowance for doubtful accounts	$ 58,000	$ 30,000
STOCKHOLDERS' EQUITY:
Preferred stock - shares authorized (in shares)	10,000,000	10,000,000
Preferred stock - shares outstanding (in shares)	0	0
Common stock - par value (in dollars per share)	$ 0.01	$ 0.01
Common stock - shares authorized (in shares)	100,000,000	100,000,000
Common stock - shares issued (in shares)	8,036,232	7,921,021
Common stock - shares outstanding (in shares)	8,036,232	7,921,021

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2012	Dec. 31, 2011
REVENUES:
Net product sales	$ 24,327,355	$ 17,422,311
License and royalty revenue	0	140,322
R&D, milestone and grant revenue	1,283,240	1,825,403
TOTAL REVENUES	25,610,595	19,388,036
Cost of product sales	14,820,604	9,997,733
GROSS MARGIN	10,789,991	9,390,303
OPERATING EXPENSES:
Research and development expenses	4,486,302	4,878,119
Selling, general and administrative expenses	4,851,587	3,424,297
TOTAL OPERATING EXPENSES	9,337,889	8,302,416
INCOME FROM OPERATIONS	1,452,102	1,087,887
OTHER INCOME (EXPENSES):
Interest income	7,911	6,298
Interest expense	(9,495)	(18,623)
TOTAL OTHER INCOME (EXPENSES)	(1,584)	(12,325)
INCOME BEFORE INCOME TAXES	1,450,518	1,075,562
Income tax provision (benefit)	509,237	(5,133,229)
NET INCOME	$ 941,281	$ 6,208,791
Basic earnings per share (in dollars per share)	$ 0.12	$ 0.79
Diluted earnings (loss) per share (in dollars per share)	$ 0.11	$ 0.73
Weighted average number of shares outstanding, basic (in shares)	7,986,030	7,874,807
Weighted average number of shares outstanding, diluted (in shares)	8,614,944	8,556,284

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2010	$ 77,799	$ 40,203,208	$ (34,472,063)	$ 5,808,944
Balance (in shares) at Dec. 31, 2010	7,779,882
Warrants and options:
Exercised	$ 1,411	286,141	0	287,552
Exercised (in shares)	141,139
Stock option compensation	$ 0	189,347	0	189,347
Net income	0	0	6,208,791	6,208,791
Balance at Dec. 31, 2011	$ 79,210	40,678,696	(28,263,272)	12,494,634
Balance (in shares) at Dec. 31, 2011	7,921,021
Common Stock:
For Services	$ 38	16,441		16,479
For Services (in shares)	3,752
Warrants and options:
For Services		8,010		8,010
Exercised	$ 1,114	119,276	0	120,390
Exercised (in shares)	111,459
Stock option compensation	$ 0	293,726	0	293,726
Net income	0	0	941,281	941,281
Balance at Dec. 31, 2012	$ 80,362	$ 41,116,149	$ (27,321,991)	$ 13,874,520
Balance (in shares) at Dec. 31, 2012	8,036,232

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Cash received from customers and grants	$ 23,810,911	$ 20,335,985
Cash paid to suppliers and employees	(23,048,243)	(18,055,252)
Interest received	7,911	6,298
Interest paid	(9,495)	(18,623)
Net cash provided by operating activities	761,084	2,268,408
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of and deposits on fixed assets	(872,442)	(726,680)
Net cash used in investing activities	(872,442)	(726,680)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from option and warrant exercises	120,390	287,552
Payment of license obligation	0	(875,000)
Payment of loan obligation	(53,551)	(54,980)
Payment of capital lease obligation	(14,576)	(24,697)
Net cash provided by (used in) financing activities	52,263	(667,125)
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(59,095)	874,603
Cash and cash equivalents - beginning of the period	3,010,954	2,136,351
Cash and cash equivalents - end of the period	2,951,859	3,010,954
RECONCILIATION OF NET INCOME TO NET CASH PROVIDED BY OPERATING ACTIVITIES:
Net Income	941,281	6,208,791
Adjustments:
Depreciation and amortization	523,278	437,828
Provision for deferred taxes	471,085	(5,155,713)
Provision for doubtful accounts	28,000	(5,000)
Share based compensation	318,215	189,347
Changes in assets and liabilities:
Accounts receivable	(1,850,908)	952,949
Inventories	(187,785)	(951,125)
Prepaid expenses and other current assets	(20,227)	(70,978)
Deposits and other assets	498	(6,248)
Accounts payable and accrued liabilities	514,423	733,557
Customer deposits and deferred revenue	23,224	(65,000)
Net cash provided by operating activities	761,084	2,268,408
Supplemental disclosures for non-cash investing and financing activities:
Deposits on manufacturing equipment transferred to fixed assets	$ 229,042	$ 0

DESCRIPTION OF BUSINESS	12 Months Ended
DESCRIPTION OF BUSINESS	Dec. 31, 2012
DESCRIPTION OF BUSINESS [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 — DESCRIPTION OF BUSINESS: Chembio Diagnostics, Inc. (the "Company" or "Chembio") and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, and market rapid diagnostic tests that detect infectious diseases. The Company's main lateral flow products are three rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, two of which were approved by the FDA in 2006; the third is sold for export only. Lateral Flow Rapid HIV tests represented nearly 56% of the Company's product revenues in 2012. The Company's products based on its patented DPP® platform represented approximately 41% of the Company's product revenues in 2012. The Company also has other rapid tests that together represented approximately 3% of sales in 2012. The Company's products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments both domestically and internationally. Chembio's products are sold under the Company's STAT-PAK®, SURE CHECK® or DPP® registered trademarks, or under the private labels of its marketing partners, for example the Clearview® label owned by Alere, Inc. ("Alere"), which is the Company's exclusive marketing partner for its rapid HIV lateral flow test products in the United States. These products employ lateral flow technologies that are proprietary and/or licensed to the Company. All of the Company's products that are currently being developed are based on its patented Dual Path Platform (DPP®), which is a unique diagnostic point-of-care platform that has certain advantages over lateral flow technology. In December 2012, the Company received FDA approval for its DPP® HIV 1/2 Assay for the detection of HIV antibodies in saliva, whole blood, serum and plasma samples.

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2012

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES:

(a)	Principles of Consolidation:

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation.

(b)	Use of Estimates:

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make assumptions and estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods covered thereby. Actual results could differ from these estimates. Judgments and estimates of uncertainties are required in applying the Company's accounting policies in certain areas. The following are some of the areas requiring significant judgments and estimates: determinations of the useful lives of assets, estimates of allowances for doubtful accounts, inventory reserves, stock-based compensation and deferred tax assets.

(c)	Fair Value of Financial Instruments:

The carrying value for cash and cash equivalents, accounts receivable and accounts payable, approximate fair value because of the immediate or short-term maturity of these financial instruments. The Company's debt relates to borrowings under its credit facilities and term loan (see Note 7), which approximates fair value due to market interest rates.

(d)	Statements of Cash Flows:

For purposes of the statements of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

(e)	Concentrations of Credit Risk:

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments and trade receivables. The Company places its temporary cash instruments with well-known financial institutions and, at times, may maintain balances in excess of the FDIC insurance limit. The Company monitors the credit ratings of the financial institutions to mitigate this risk. Concentration of credit risk with respect to trade receivables is principally mitigated by the Company's ability to obtain letters of credit from certain foreign customers, and its diverse customer base both in number of customers and geographic locations. We currently do not require collateral for accounts receivable.

(f)	Inventories:

Inventories, consisting of material, labor and manufacturing overhead, are stated at the lower of cost or market. Cost is determined on the first-in, first-out method.

(g)	Fixed Assets:

Fixed assets are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which range from three to seven years. Leasehold improvements are amortized over the useful life of the asset or the lease term, whichever is shorter. Deposits paid for fixed assets are capitalized and not depreciated until the related asset is placed in service.

(h)	License Agreement:

In February 2008, the Company entered into a sublicense agreement for which it had initially recorded an asset of $1,000,000. This asset is being expensed over an estimated economic life of ten years, based on the expected lifespan of our then current HIV products. The current portion of this asset is $100,000 as of December 31, 2012 and 2011 and is reported in prepaid expenses and other current assets. The long-term portion as of December 31, 2012 and 2011 is $400,000 and $500,000, respectively and is reflected in other assets on the consolidated balance sheet.

(i)	Impairment of Long-Lived Assets and Intangible Assets

Long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment. If there are indications of impairment, the Company uses future undiscounted cash flows of the related asset or asset grouping over the remaining life in measuring whether the assets are recoverable. In the event such cash flows are not expected to be sufficient to recover the recorded asset values, the assets are written down to their estimated fair value. We believe that the carrying values of our long-lived tangible and intangible assets were realizable at December 31, 2012 and 2011, respectively.

(j)	Revenue Recognition:

The Company recognizes revenue for product sales in accordance with ASC 605, revenue is recognized when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price is fixed and determinable, and collectability is reasonably assured. Revenue typically is recognized at time of shipment. Sales are recorded net of discounts, rebates and returns. As of December 31, 2012 and 2011, an aggregate of $23,000 and none, respectively, of customer deposits were not recognized.

For certain contracts, the Company recognizes revenue from non-milestone contracts and grant revenues when earned. Grants are invoiced after expenses are incurred. Revenues from projects or grants funded in advance are deferred until earned. As of December 31, 2012 and 2011, all advanced revenues were earned.

The Company follows Financial Accounting Standards Board ("FASB") issued authoritative guidance ("guidance") prospectively for the recognition of revenue under the milestone method. The Company applies the milestone method of revenue recognition for certain collaborative research projects defining milestones at the inception of the agreement.

(k)	Research and Development:

Research and development (R&D) costs are expensed as incurred.

(l)	Stock-Based Compensation:

Stock-based compensation expense is calculated using the Black-Scholes valuation model based on awards ultimately expected to vest, reduced for forfeitures, and expensed on a straight-line basis over the requisite service period of the grant.

(m)	Income Taxes:

The Company accounts for income taxes under an asset and liability approach which recognizes deferred tax assets and liabilities based on the difference between the financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse.

The Company follows a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The guidance relates to, among other things, classification, accounting for interest and penalties associated with tax positions, and disclosure requirements. Any interest and penalties accrued related to uncertain tax positions will be recorded in tax expense.

(n)	Earnings Per Share

On May 30, 2012, the Company effected a 1-for-8 reverse split of its common stock. This was done to allow the Company to move to the NASDAQ trading market from the OTCQB market, which occurred on June 7, 2012. As a result of the stock split, the outstanding 63,967,263 common shares were reduced to 7,995,918 outstanding common shares on May 30, 2012. The effect of the reverse stock split has been retroactively reflected for all periods in these financial statements.

The following weighted average shares were used for the computation of basic and diluted earnings per share:

	For the years ended
	December 31, 2012		December 31, 2011
Basic		7,986,030		7,874,807
		-		-
Diluted		8,614,944		8,556,284

Basic earnings per share is computed by dividing net earnings attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per share for the year ended December 31, 2012 and 2011 reflects the potential dilution from the exercise or conversion of other securities into common stock.

The following securities, presented on a common share equivalent basis, have been used in the diluted per share computations:

	For the years ended
	December 31, 2012		December 31, 2011

1999 and 2008 Plan Stock Options		628,914		681,477

There were 161,464 and 182,343 options and warrants outstanding as of December 31, 2012 and 2011, respectively, which were not included in the calculation of diluted income per share for the years ended because their effect would have been anti-dilutive.

(o)	Recent Accounting Pronouncements Affecting the Company:

New accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standards setting bodies that we adopt according to the various timetables the FASB specifies. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position or cash flow.

INVENTORIES

12 Months Ended

Dec. 31, 2012

INVENTORIES [Abstract]

INVENTORIES

NOTE 3 — INVENTORIES:

Inventories consist of the following at:

	December 31, 2012		December 31, 2011
Raw materials	$	1,418,071	$	1,340,177
Work in process		561,530		390,162
Finished goods		508,470		569,947
	$	2,488,071	$	2,300,286

FIXED ASSETS

12 Months Ended

Dec. 31, 2012

FIXED ASSETS [Abstract]

FIXED ASSETS

NOTE 4 — FIXED ASSETS:

Fixed assets consist of the following at:

	December 31, 2012			December 31, 2011
Machinery and equipment	$	2,439,596		$	1,982,926
Furniture and fixtures		287,412			221,299
Computer and telephone equipment		151,737			460,842
Leasehold improvements		798,049			595,492
Automobiles		29,228			29,228
		3,706,022			3,289,787
Less accumulated depreciation and amortization		(2,278,376	)		(2,227,511	)
	$	1,427,646		$	1,062,276

There were no capital leases at the end of December 31, 2012. Included in fixed assets is $24,000, net of accumulated depreciation of assets held under capital leases as of December 31, 2011. Fixed assets at December 31, 2012 also include $323,000 in equipment, which has been delivered and set-up but is undergoing validation and as such is currently not being depreciated. Depreciation expense for the 2012 and 2011 years aggregated $423,000 and $338,000, respectively.

As of December 31, 2012 and 2011, the Company had paid deposits on various pieces of equipment aggregating $223,584 and $139,790, respectively. The Company is further committed to an additional obligation of $61,071 as various milestones are achieved by the various vendors.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2012

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 5 — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES:

Accounts payable and accrued liabilities consist of the following:

	December 31, 2012		December 31, 2011
Accounts payable – suppliers	$	1,686,431	$	1,258,465
Accrued commissions		238,150		205,588
Accrued royalties / license fees		583,923		480,297
Accrued payroll		262,439		174,398
Accrued vacation		181,636		156,884
Accrued bonuses		155,663		284,375
Accrued expenses – other		195,681		229,493
TOTAL	$	3,303,923	$	2,789,500

DEFERRED RESEARCH AND DEVELOPMENT REVENUE	12 Months Ended
DEFERRED RESEARCH AND DEVELOPMENT REVENUE	Dec. 31, 2012
DEFERRED RESEARCH AND DEVELOPMENT REVENUE [Abstract]
DEFERRED RESEARCH AND DEVELOPMENT REVENUE	NOTE 6 — DEFERRED RESEARCH AND DEVELOPMENT REVENUE: The Company recognizes income from R&D milestones when those milestones are reached and non-milestone contracts and grants when earned. Grants are invoiced after expenses are incurred. Any projects or grants funded in advance are deferred until earned. As of December 31, 2012 and 2011, there were no unearned advanced revenues.

TERM NOTE, REVOLVING DEMAND NOTE, VEHICLE FINANCING AND LICENSE FEE PAYABLE	12 Months Ended
	Dec. 31, 2012
TERM NOTE, REVOLVING DEMAND NOTE, VEHICLE FINANCING AND LICENSE FEE PAYABLE [Abstract]
TERM NOTE, REVOLVING DEMAND NOTE, VEHICLE FINANCING AND LICENSE FEE PAYABLE	NOTE 7 — TERM NOTE, REVOLVING DEMAND NOTE, VEHICLE FINANCING AND LICENSE FEE PAYABLE: In June 2010, the Company entered into three agreements with HSBC Bank, NA ("HSBC"). The three agreements were: 1) a secured term note ("Term Note") of $250,000 to be repaid over sixty months; 2) a secured revolving demand note ("Demand Note") up to $250,000; and 3) a loan and security agreement ("Security Agreement"). The Term Note is payable at $4,775 per month in arrears. The payment was calculated by amortizing the $250,000 note over 60 months at an interest rate of 5.5% per annum. The Term Note matures June, 2015 and is secured under the terms of the Security Agreement. In January 2013, the Company repaid this Term Note in full without penalty. The Demand Note allows the Company to draw on the line from time to time an amount up to an aggregate of $250,000 outstanding at any one time. The accrued interest on the Demand Note is payable monthly at an interest rate equal to one-quarter percent above prime per annum. The Company can repay any or all of the principal balance outstanding at any time. This is a demand note and is subject to annual reviews, as well as a 30-day clean-up, during which there can be no amounts outstanding. The Security Agreement contains covenants that place restrictions on the Company's operations, including covenants relating to mergers, debt restrictions, capital expenditures, tangible net worth, net profit, leverage, fixed charge coverage, employee loan restrictions, distribution restrictions (common stock and preferred stock), dividend restrictions, restrictions on lease payments to affiliates, restrictions on changes in business, asset sale restrictions, restrictions on acquisitions and intercompany transactions, restrictions on fundamental changes. The Security Agreement also requires that the Company maintain a minimum tangible net worth at all times of greater than $3,000,000 and EBITDA to CMLTD plus interest cannot be less than 1.25 to 1.00 for any fiscal year. (EBITDA is earnings before interest, taxes, depreciation and amortization; CMLTD is defined as, for any one-year period, the current scheduled principal payments required to be paid for the applicable period.). The Company was in compliance with all required financial covenants at December 31, 2012. In July 2011, the Company entered into additional agreements with HSBC Bank, NA ("HSBC"). The agreements were: 1) a secured revolving demand note for equipment ("Equipment Note") up to $500,000, convertible to a term note after one year; and 2) a loan and security agreement ("Security Agreement"). The Equipment Note allows the Company to draw on the line from time to time an amount up to an aggregate of $500,000 outstanding at any one time. The accrued interest on the Equipment Note is payable monthly at an interest rate equal to one-quarter percent above prime per annum. The Company can repay any or all of the principal balance outstanding at any time. The Equipment Note will be converted into a 60-month term note at the end of one year. As the Company did not draw down on this line the Demand Note and the Equipment Note expired in July of 2012. The Security Agreement contains covenants that place restrictions on the Company's operations, including covenants relating to mergers, debt restrictions, capital expenditures, tangible net worth, net profit, leverage, fixed charge coverage, employee loan restrictions, distribution restrictions (common stock and preferred stock), dividend restrictions, restrictions on lease payments to affiliates, restrictions on changes in business, asset sale restrictions, restrictions on acquisitions and intercompany transactions, restrictions on fundamental changes. The Company was in compliance with all required financial covenants when the notes expired. The Company currently maintains its operating, payroll, and primary cash accounts at HSBC. The balance due on the Term Note as of December 31, 2012 was $133,000. Future minimum payments under the Term Note, excluding interest, as of December 31, 2012 is not shown as the balance was paid in full on January 17, 2013 in the amount of $129,000. In June 2009, the Company purchased a vehicle for use by the CEO and obtained financing in the amount of $29,000. The financing is for a period of 3 years, is secured by the vehicle and is guaranteed by the CEO. The financing agreement provides for monthly principal and interest payments of $849 and carries an interest rate of 2.9% per annum. There was no balance due on this loan as of December 31, 2012.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

INCOME TAXES

12 Months Ended

Dec. 31, 2012

INCOME TAXES [Abstract]

INCOME TAXES

NOTE 8 — INCOME TAXES:

The provision (benefit) for income taxes for the years ended December 31, 2012 and 2011, is comprised of the following:

	2012		2011
Current
Federal	$	33,054	$	22,082
State		5,098		402
Total current provision		38,152		22,484

Deferred
Federal		464,005		(5,155,713	)
State		7,080		-
Total deferred provision		471,085		(5,155,713	)

Total provision	$	509,237	$	(5,133,229	)

The Company had an ownership change as described in Internal Revenue Code Sec. 382 during 2004 ("2004 change"). As a result, the Company's net operating losses prior to the 2004 change of $5,832,516 are subject to an annual limitation of $150,608 and for the first five (5) years are entitled to a BIG (Built-In-Gains) of $488,207 per year. These net operating losses expire in 2018 through 2024.

The Company had a second ownership change during 2006 ("2006 change"). The net operating losses incurred between the 2004 change and the 2006 change of $8,586,861 are subject to an annual limitation of $1,111,831 and for the first five (5) years are entitled to a BIG of $1,756,842 per year. These net operating losses expire in 2018 through 2028.

After applying the above limitations, at December 31, 2012, the Company has post-change net operating loss carry-forwards of approximately $12,274,761 which expire between 2020 and 2028. In addition the Company has research and development tax credit carryforwards of approximately $711,000 for the year ended December 31, 2012, which expire between 2025 and 2032.

Prior to 2011 and through September 30, 2011, the Company had a full valuation allowance recorded against deferred tax assets. In the fourth quarter of 2011, based on the Company's sustained profitable operating performance over the past three years and its positive outlook for taxable income in the future, the Company reevaluated its deferred tax asset. Based upon the guidance under ASC 740 that it was more likely than not that the Company would realize the benefit of such deferred tax assets, the Company reversed $5,156,000 of the valuation allowance previously recorded against its deferred tax assets. The Company still maintains a full valuation allowance on research and development tax credits.

Deferred tax assets consist of at December 31,

	2012			2011
Current assets
Inventory reserves	$	224,694		$	260,665
Accrued expenses		226,740			145,426
Net current deferred asset	$	451,434		$	406,091

Noncurrent assets
Net operating loss carry-forwards	$	4,236,008		$	4,837,466
Research and development credit		711,444			581,576
Other credits		97,234			-
Other		99,097			132,734
Gross noncurrent deferred tax assets		5,143,783			5,551,776
Depreciation		(199,145	)		(220,578	)
Noncurrent deferred tax assets		4,944,638			5,331,198
Less valuation allowances		(711,444	)		(581,576	)
Net noncurrent deferred tax assets	$	4,233,194		$	4,749,622

A reconciliation of the Federal statutory rate to the effective rate applicable to income (loss) before income taxes is as follows:

	Year Ending December 31,
	2012			2011
Federal income tax at statutory rates		34	%		34	%
State income taxes, net of federal benefit		.7	%		0	%
Nondeductible expenses		5.4	%		6.4	%
Change in valuation allowance		8.9	%		(514.3	)%
Tax credits		(8.9	)%		-
Change in tax rates		(5.2	)%		-
Other		.2	%		(.7	)%
Income tax (benefit)		35.1	%		(474.6	)%

Interest and penalties, if any, related to income tax liabilities are included in income tax expense. As of December 31, 2012, the Company does not have a liability for uncertain tax positions.

The Company files Federal and New York state income tax returns. Tax years for fiscal 2009 through 2011 are open and potentially subject to examination by the federal and New York state taxing authorities.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

STOCKHOLDERS' EQUITY	12 Months Ended
STOCKHOLDERS' EQUITY	Dec. 31, 2012
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	NOTE 9 — STOCKHOLDERS' EQUITY: (a) Common Stock During 2012, options to purchase 111,459 shares of the Company's common stock were exercised at exercise prices ranging from of $1.04 to $1.76. In March 2012, June 2012, September 2012 and December 2012, the Company issued 938 shares of common stock on each date to a consultant as part of the consultant's compensation. During 2011, options to purchase 76,927 shares of the Company's common stock were exercised at exercise prices ranging from of $1.04 to $1.76. (b) Preferred Stock The Company has 10,000,000 shares of preferred stock authorized and none outstanding. These shares can become issuable upon an approved resolution by the board of directors and the filing of a Certificate of Designation with the state of Nevada. (c) Options On February 16, 2012, the Company issued 25,392 options to purchase common stock to executives of the Company as part of their 2011 bonus. The options are exercisable immediately at $4.00 per share, which was the last traded price of the common stock on that day, and they expire five years from date of issue. In March 2012, the Company issued 3,750 options to purchase shares of the Company's common at an exercise price of $4.00 per share to a consultant as part of the consultant's compensation. On each of March 19, 2012, June 19, 2012, September 19, 2012 and December 19, 2012, 938 of these options vested. These options were valued using a Black-Scholes model at $8,010, all of which was expensed in the year ended December 31, 2012. The options are being accounted for under the variable method as per ASC 505 and $50 of the expense was reduced attributable to this method. During the third quarter of 2012, the Company issued 72,000 options to purchase common stock to newly-hired vice-presidents of the Company. The options are exercisable in three equal annual installments on the anniversary of the issuance starting one year from date of issue. An allotment of 36,000 options issued to one of the new vice presidents have an exercise price of $5.11 per share, and the 36,000 options that were issued to the other new vice president have an exercise price of $4.45 per share, which in each case was the last traded price of the common stock on the day issued. The options expire five years from date of issue. (d) Warrants As of December 31, 2012, the Company had no warrants outstanding to purchase shares of common stock. On April 26, 2011, warrants to purchase 513,698 shares of common stock were exercised at $.40 per share. The Company received $205,479 for this exercise. As of December 31, 2011, the Company had warrants outstanding to purchase 33,381 shares of common stock at a price of $.81. On February 5, 2012 these warrants to purchase shares of common stock expired.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

RIGHTS AGREEMENT	12 Months Ended
RIGHTS AGREEMENT	Dec. 31, 2012
RIGHTS AGREEMENT [Abstract]
RIGHTS AGREEMENT	NOTE 10 — RIGHTS AGREEMENT: In March 2010, the Company entered into a Rights Agreement (the "Rights Agreement") between the Company and Action Stock Transfer Corp., as Rights Agent. Pursuant to the Rights Agreement, the Company declared a dividend distribution of one preferred share purchase right (a "Right") for each outstanding share of Common Stock, $0.01 par value (the "Common Stock"), of the Company. The Board of Directors set the payment date for the distribution of the Rights as March 8, 2010, and the Rights were distributed to the Company's shareholders of record on that date. The description and terms of the Rights are set forth in the Rights Agreement. Rights Initially Not Exercisable. The Rights are not exercisable until a Distribution Date. Until a Right is exercised, the holder thereof, as such, will have no rights as a shareholder of the Company, including, without limitation, the right to vote or to receive dividends. Separation and Distribution of Rights. The Rights will be evidenced by the certificates for shares of Common Stock registered in the names of the holders thereof, and not by separate rights certificates until the earlier to occur of (i) the close of business on the tenth business day following a public announcement that an Acquiring Person (as defined in the Rights Agreement) acquired a Combined Ownership (as defined in the Rights Agreement) of 15% or more of the outstanding shares of the Common Stock (the "Shares Acquisition Date") or (ii) the later of (A) the close of business on the tenth business day (or such later date as may be determined by action of the Board of Directors prior to such time as any person or group of affiliated or associated persons becomes an Acquiring Person) after the date that a tender or exchange offer or intention to commence a tender or exchange offer by any person is first published, announced, sent or given within the meaning of Rule 14d-4(A) under the Securities Exchange Act of 1934, as amended, the consummation of which would result in any person having Combined Ownership of 15% or more of the outstanding shares of the Common Stock, or (B) if such a tender or exchange offer has been published, announced, sent or given before the date of the Rights Agreement, then the close of business on the tenth business day after the date the Rights Agreement was entered into (or such later date as may be determined by action of the Board of Directors prior to such time as any person becomes an Acquiring Person); (the earlier of such dates referred to in (i) and (ii), which date may include any such date that is after the date of the Rights Agreement but prior to the issuance of the Rights, being called the "Distribution Date").

EMPLOYEE STOCK OPTION PLAN

12 Months Ended

Dec. 31, 2012

EMPLOYEE STOCK OPTION PLAN [Abstract]

EMPLOYEE STOCK OPTION PLAN

NOTE 11 — EMPLOYEE STOCK OPTION PLAN:

The Company has a 1999 Stock Option Plan ("SOP") originally covering 187,500 shares of Common Stock. Under the terms of the SOP, the Compensation Committee of the Company's board is authorized to grant incentive options to key employees and to grant non-qualified options to key employees and key individuals. The options become exercisable at such times and under such conditions as determined by the Compensation Committee. The SOP was amended at the Company's 2005 stockholders' meeting. The number of options under the SOP was increased to cover 375,000 shares of common stock. It was also amended to allow independent directors to be eligible for grants under the portion of the SOP concerning non-qualified options. As of December 31, 2012, there were 135,191 outstanding options under this SOP. No additional options may be issued under the SOP more than 10 years after its adoption

Effective June 3, 2008, the Company's stockholders voted to approve the 2008 Stock Incentive Plan ("SIP"), with 625,000 shares of Common Stock available to be issued. At the Annual Stockholder meeting on September 22, 2011 the Company's stockholders voted to approve an increase to the shares of Common Stock issuable under the SIP by 125,000 to 750,000. Under the terms of the SIP, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted. Awards can be stock options, restricted stock and/or restricted stock units. The awards become vested at such times and under such conditions as determined by the Compensation Committee. As of December 31, 2012, there were 84,584 options exercised, 596,455 options outstanding and 68,961 options still available to be issued under the SIP.

The Company's results for the years ended December 31, 2012 and 2011 include stock-based compensation expense totaling $294,000 and $189,000, respectively. Such amounts have been included in the Consolidated Statements of Operations within cost of goods sold ($49,000 and $18,000, respectively), research and development ($71,000 and $56,000, respectively) and selling, general and administrative expenses ($174,000 and $115,000, respectively). In accordance with ASC 718 the Company has not recorded a deferred tax asset related to the net operating losses resulting from the exercise of disqualifying stock options in the accompanying financial statements. The cumulative amount of unrecognized tax benefits at December 31, 2012 was immaterial, and if the Company is able to utilize this benefit in the future it would result in a credit to additional paid-in capital.

Stock option compensation expense in the years ended December 31, 2012 and 2011 represents the estimated fair value of options outstanding which is being amortized on a straight-line basis over the requisite vesting period of the entire award.

The weighted average estimated fair value of stock options granted in the years ended December 31, 2012 and 2011 was $3.27 and $1.76 per share, respectively. The fair value of options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of our stock and other contributing factors. The expected term is based on the Company's historical experience with similar type options.

The weighted-average assumptions made in calculating the fair values of options are as follows:

	For the years ended
	December 31, 2012			December 31, 2011
Expected term (in years)		4-5			3.75
Expected volatility		99.6-115.77	%		97.11-117.9	%
Expected dividend yield		n/a			n/a
Risk-free interest rate		.33-.37	%		.57-1.24	%

The Company granted 97,392 and 3,750 new options during the year ended December 31, 2012 to employees and a consultant (non-plan options), respectively at an average exercise price of $4.58 and $4.00, respectively per share.

The following table provides stock options activity for the year ended December 31, 2012:

Stock Options	Number of Shares			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at December 31, 2011		765,903		$	1.68	2.61 years	$	1,339,693

Granted		97,392		$	4.58
Exercised		(111,459	)	$	1.08
Forfeited/expired/cancelled		(20,190	)	$	3.89
Outstanding at December 31, 2012		731,646		$	2.23	2.19 years	$	3,460,686

Exercisable at December 31, 2012		511,824		$	1.45	1.57 years	$	2,438,665

The following table summarizes information about stock options outstanding at December 31, 2012:

		Stock Options Outstanding								Stock Options Exercisable
Range of Exercise Prices		Shares		Average Remaining Contract Life (Year)		Weighted Average Exercise Price		Aggregate Intrinsic Value		Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value
$	0 to 1.50		397,333		1.29	$	1.04	$	1,466,159		378,583	$	1.04	$	1,396,971
1.5001 to 2			41,441		0.13		1.76		123,080		41,441		1.76		123,080
2.0001 to 3.5			131,250		3.28		2.62		277,318		62,500		2.54		136,625
3.5001 to 4.5			125,622		3.83		4.26		59,042		29,300		3.95		22,775
4.50001 to 8			36,000		4.60		5.11		-		-		-		-
Total			731,646		2.18	$	2.12	$	1,925,599		511,824	$	1.45	$	1,679,451

As of December 31, 2012, there was $305,000 of net unrecognized compensation cost related to stock options that are not vested, which is expected to be recognized over a weighted average period of approximately .81 years. The total fair value of shares vested during the years ended December 31, 2012 and 2011, was $144,000 and $149,000, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

GEOGRAPHIC INFORMATION

12 Months Ended

Dec. 31, 2012

GEOGRAPHIC INFORMATION [Abstract]

GEOGRAPHIC INFORMATION

NOTE 12 — GEOGRAPHIC INFORMATION:

FASB Guidance establishes standards for the way that business enterprises report information about operating segments in financial statements and requires that those enterprises report selected information. It also establishes standards for related disclosures about product and services, geographic areas, and major customers.

The Company produces only one group of similar products known collectively as "rapid medical tests". Management believes that it operates in a single business segment. Net sales by geographic area are as follows:

	For the years ended
	December 31, 2012		December 31, 2011
Africa	$	2,669,140	$	2,340,635
Asia		658,831		1,784,817
Europe		54,280		57,206
North America		8,630,956		8,522,878
South America		12,314,148		4,716,775
	$	24,327,355	$	17,422,311

Sales to Africa increased in 2012 primarily due to increased sales in Uganda by approximately $106,000 and Nigeria by approximately $298,000. Sales in Asia decreased from sales in the Middle East by $1.22 million. Sales in 2012 and 2011 to North America were primarily from sales in the U.S of approximately $7.72 million and $7.21 million, respectively and sales in 2012 and 2011 to South America were primarily from sales in Brazil of approximately $10.30 million and $4.66 million, respectively.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2012

COMMITMENTS AND CONTINGENCIES [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 13 — COMMITMENTS AND CONTINGENCIES:

Employment Contracts:

The Company has contracts with two key employees. The contracts call for salaries presently aggregating $590,000 per year. One contract expires in May 2013 and one contract expires in March 2016. The following table is a schedule of future minimum salary commitments:

2013	$	422,500
2014		300,000
2015		300,000
2016		50,000

Pension Plan:

The Company has a 401(k) plan established for its employees. Effective January 1, 2011 the Company elected to match 40% of the first 5% (or 2% of salary) that an employee contributes to their 401(k) plan. Expenses related to this matching contribution aggregated $64,604 and $61,628 for the years ended December 31, 2012 and 2011, respectively.

Obligations Under Operating Leases:

The Company leases industrial space used for office, R&D and manufacturing facilities, currently with a monthly rent of $20,530. The current leases expire on April 30, 2014. The monthly rent for the year will increase by the lower of (i) the change in the consumer price index, or (ii) two and one half percent.

The following is a schedule of future minimum rental commitments (assuming no increases):

Years ending December 31,

2013	$	246,360
2014		82,120
	$	328,480

Rent expense was $231,700 and $177,200 for the years ended December 31, 2012 and 2011, respectively.

Economic Dependency:

The following table delineates sales the Company had to customers in excess of 10% of total sales for the periods indicated:

									Accounts
	For the years ended								Receivable As of
	December 31, 2012				December 31, 2011				December 31, 2012		December 31, 2011
	Sales		% of Sales		Sales		% of Sales
Customer 1	$	7,778,688		32	$	7,208,712		41	$	879,089		782,300
Customer 2		10,299,216		42		4,662,607		27		1,668,156		685,692
Customer 3		*		*		1,713,390		10		596		450,000

In the table above the asterisk (*) indicates that sales to the customer did not exceed 10% for the period indicated.

The following table delineates purchases the Company had with vendors in excess of 10% of total purchases for the periods indicated.

Accounts

For the years ended

Payable As of

December 31, 2012

December 31, 2011

December 31, 2012

December 31, 2011

Purchases

% of Purc.

Purchases

% of Purc.

Vendor 1

817,293

114,895

3,380

Vendor 2

778,793

76,932

23,327

In the table above the asterisk (*) indicates that purchases from the vendor did not exceed 10% for the period indicated

The Company currently buys materials which are purchased under intellectual property rights agreements and are important components in its products. Management believes that other suppliers could provide similar materials on comparable terms. A change in suppliers, however, could cause a delay in manufacturing and a possible loss of sales, which would affect operating results adversely.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS

12 Months Ended

Dec. 31, 2012

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS [Abstract]

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS

NOTE 14 — COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS:

In 2012 and 2011, the Company earned $1.3 million and $1.8 million, respectively from research revenues and milestones. The Company is now involved in additional feasibility and development contracts related to its DPP® technology. The total expended on R&D in 2012 and 2011, was approximately $3.1 million and $3.1 million, respectively.

a.	Oswaldo Cruz Foundation/Fiocruz:

During 2008, the Company signed four Agreements with the Bio-Manguinhos unit of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ") for the supply, license and transfer of certain products and related technologies from the Company to FIOCRUZ. The agreements are for the following rapid test products: i) DPP® HIV 1/2 Screen, ii) DPP® HIV 1/2 Confirmatory, iii) DPP® Leptospirosis and iv) DPP® Leishmaniasis. These Agreements provide for a staged technology transfer collaboration pursuant to which FIOCRUZ will ultimately be able to fully manufacture the applicable product for supply in Brazil provided certain minimum purchases of products and related components have occurred.

In 2011, FIOCRUZ informed the Company that ANVISA (the Brazilian regulatory agency) had approved the DPP® Leishmaniasis, Syphilis Screen and Leptospirosis assays for use in Brazil. This approval triggered milestone events of $305,000, $100,000 and $100,000, respectively. In accordance with guidance, management has concluded that the FIOCRUZ events recorded in 2011 met the definition of milestone events. The Company earned an aggregate of none and $505,000 in milestone revenues from FIOCRUZ for the years ended December 31, 2012 and 2011, respectively.

Under these contracts, there are additional royalties and purchase commitments due to the Company over the remaining life of the Agreement.

b.	National Institutes of Health (NIH) Grant:

In June 2009, the Company received a $3 million, three-year grant from the United States National Institutes of Health to complete development of a test for Leptospirosis. Grants are invoiced after expenses are incurred. The Company earned, for the years ended December 31, 2012 and 2011, $270,000 and $690,000, respectively from this grant. The Company has earned an aggregate of $2,756,000 from this grant from inception through December 31, 2012, of which $898,000 was paid to sub-contractors.

In March 2011, the Company received a $2.4 million, three-year grant from the United States National Institutes of Health to complete development of a test for Tuberculosis. Grants are invoiced after expenses are incurred. The Company earned, for the years ended December 31, 2012 and 2011, $682,000 and $350,000, respectively from this grant. The Company has earned $1,377,000 from this grant from inception through December 31, 2012, of which $345,000 was paid to sub-contractors.

c.	Battelle/CDC DPP® Influenza Immunity Test:

In July 2012, the Company entered into a follow-on, milestone-based development agreement of up to $480,000 based on Chembio's previous successful initial development of a multiplex rapid point-of-care ("POC") influenza immunity test utilizing its patented Dual Path Platform (DPP®) technology. The agreement contemplates a period of approximately nine months in which the follow-on development activity is to be completed. As of December 31, 2012 the Company has earned $278,000

Governmental Regulation:

All of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration (FDA), United States Department of Agriculture, certain state and local agencies, and/or comparable regulatory bodies in other countries. Most aspects of development, production, and marketing, including product testing, authorizations to market, labeling, promotion, manufacturing, and record keeping are subject to review. After marketing approval has been granted, Chembio must continue to comply with governmental regulations. Failure to comply with these regulations can result in significant penalties.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23218-108380

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Audit and Accounting Guide (AAG)
-Number AAG-FGC
-Paragraph 56, 57
-IssueDate 2006-05-01
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 68
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2012

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Principles of Consolidation

(a)	Principles of Consolidation:

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

(b)	Use of Estimates:

Fair Value of Financial Instruments

(c)	Fair Value of Financial Instruments:

Statements of Cash Flows

(d)	Statements of Cash Flows:

For purposes of the statements of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

Concentrations of Credit Risk

(e)	Concentrations of Credit Risk:

Inventories

(f)	Inventories:

Inventories, consisting of material, labor and manufacturing overhead, are stated at the lower of cost or market. Cost is determined on the first-in, first-out method.

Fixed Assets

(g)	Fixed Assets:

License Agreement

(h)	License Agreement:

Impairment of Long-Lived Assets and Intangible Assets

(i)	Impairment of Long-Lived Assets and Intangible Assets

Revenue Recognition

(j)	Revenue Recognition:

Research and Development

(k)	Research and Development:

Research and development (R&D) costs are expensed as incurred.

Stock-Based Compensation

(l)	Stock-Based Compensation:

Income Taxes

(m)	Income Taxes:

Earnings Per Share

(n)	Earnings Per Share

The following weighted average shares were used for the computation of basic and diluted earnings per share:

	For the years ended
	December 31, 2012		December 31, 2011
Basic		7,986,030		7,874,807
		-		-
Diluted		8,614,944		8,556,284

The following securities, presented on a common share equivalent basis, have been used in the diluted per share computations:

	For the years ended
	December 31, 2012		December 31, 2011

1999 and 2008 Plan Stock Options		628,914		681,477

Recent Accounting Pronouncements Affecting the Company

(o)	Recent Accounting Pronouncements Affecting the Company:

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2012

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Schedule of weighted average shares used for computation of basic and diluted earnings per share

The following weighted average shares were used for the computation of basic and diluted earnings per share:

	For the years ended
	December 31, 2012		December 31, 2011
Basic		7,986,030		7,874,807
		-		-
Diluted		8,614,944		8,556,284

Schedule of common share equivalent basis, used in diluted per share computations

The following securities, presented on a common share equivalent basis, have been used in the diluted per share computations:

	For the years ended
	December 31, 2012		December 31, 2011

1999 and 2008 Plan Stock Options		628,914		681,477

INVENTORIES (Tables)

12 Months Ended

Dec. 31, 2012

INVENTORIES [Abstract]

Schedule of inventories

Inventories consist of the following at:

	December 31, 2012		December 31, 2011
Raw materials	$	1,418,071	$	1,340,177
Work in process		561,530		390,162
Finished goods		508,470		569,947
	$	2,488,071	$	2,300,286

FIXED ASSETS (Tables)

12 Months Ended

Dec. 31, 2012

FIXED ASSETS [Abstract]

Schedule of fixed assets

Fixed assets consist of the following at:

	December 31, 2012			December 31, 2011
Machinery and equipment	$	2,439,596		$	1,982,926
Furniture and fixtures		287,412			221,299
Computer and telephone equipment		151,737			460,842
Leasehold improvements		798,049			595,492
Automobiles		29,228			29,228
		3,706,022			3,289,787
Less accumulated depreciation and amortization		(2,278,376	)		(2,227,511	)
	$	1,427,646		$	1,062,276

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2012

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Abstract]

Schedule of accounts payable and accrued liabilities

Accounts payable and accrued liabilities consist of the following:

	December 31, 2012		December 31, 2011
Accounts payable – suppliers	$	1,686,431	$	1,258,465
Accrued commissions		238,150		205,588
Accrued royalties / license fees		583,923		480,297
Accrued payroll		262,439		174,398
Accrued vacation		181,636		156,884
Accrued bonuses		155,663		284,375
Accrued expenses – other		195,681		229,493
TOTAL	$	3,303,923	$	2,789,500

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2012

INCOME TAXES [Abstract]

Schedule of provision (benefit) for income taxes

The provision (benefit) for income taxes for the years ended December 31, 2012 and 2011, is comprised of the following:

	2012		2011
Current
Federal	$	33,054	$	22,082
State		5,098		402
Total current provision		38,152		22,484

Deferred
Federal		464,005		(5,155,713	)
State		7,080		-
Total deferred provision		471,085		(5,155,713	)

Total provision	$	509,237	$	(5,133,229	)

Schedule of deferred tax assets

Deferred tax assets consist of at December 31,

	2012			2011
Current assets
Inventory reserves	$	224,694		$	260,665
Accrued expenses		226,740			145,426
Net current deferred asset	$	451,434		$	406,091

Noncurrent assets
Net operating loss carry-forwards	$	4,236,008		$	4,837,466
Research and development credit		711,444			581,576
Other credits		97,234			-
Other		99,097			132,734
Gross noncurrent deferred tax assets		5,143,783			5,551,776
Depreciation		(199,145	)		(220,578	)
Noncurrent deferred tax assets		4,944,638			5,331,198
Less valuation allowances		(711,444	)		(581,576	)
Net noncurrent deferred tax assets	$	4,233,194		$	4,749,622

Schedule of reconciliation of the Federal statutory rate to the effective rate applicable to income (loss) before income taxes

A reconciliation of the Federal statutory rate to the effective rate applicable to income (loss) before income taxes is as follows:

	Year Ending December 31,
	2012			2011
Federal income tax at statutory rates		34	%		34	%
State income taxes, net of federal benefit		.7	%		0	%
Nondeductible expenses		5.4	%		6.4	%
Change in valuation allowance		8.9	%		(514.3	)%
Tax credits		(8.9	)%		-
Change in tax rates		(5.2	)%		-
Other		.2	%		(.7	)%
Income tax (benefit)		35.1	%		(474.6	)%

EMPLOYEE STOCK OPTION PLAN (Tables)

12 Months Ended

Dec. 31, 2012

EMPLOYEE STOCK OPTION PLAN [Abstract]

Assumptions made in calculating the fair values of options

The weighted-average assumptions made in calculating the fair values of options are as follows:

	For the years ended
	December 31, 2012			December 31, 2011
Expected term (in years)		4-5			3.75
Expected volatility		99.6-115.77	%		97.11-117.9	%
Expected dividend yield		n/a			n/a
Risk-free interest rate		.33-.37	%		.57-1.24	%

Stock options activity

The following table provides stock options activity for the year ended December 31, 2012:

Stock Options	Number of Shares			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at December 31, 2011		765,903		$	1.68	2.61 years	$	1,339,693

Granted		97,392		$	4.58
Exercised		(111,459	)	$	1.08
Forfeited/expired/cancelled		(20,190	)	$	3.89
Outstanding at December 31, 2012		731,646		$	2.23	2.19 years	$	3,460,686

Exercisable at December 31, 2012		511,824		$	1.45	1.57 years	$	2,438,665

Summary of stock options outstanding

The following table summarizes information about stock options outstanding at December 31, 2012:

		Stock Options Outstanding								Stock Options Exercisable
Range of Exercise Prices		Shares		Average Remaining Contract Life (Year)		Weighted Average Exercise Price		Aggregate Intrinsic Value		Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value
$	0 to 1.50		397,333		1.29	$	1.04	$	1,466,159		378,583	$	1.04	$	1,396,971
1.5001 to 2			41,441		0.13		1.76		123,080		41,441		1.76		123,080
2.0001 to 3.5			131,250		3.28		2.62		277,318		62,500		2.54		136,625
3.5001 to 4.5			125,622		3.83		4.26		59,042		29,300		3.95		22,775
4.50001 to 8			36,000		4.60		5.11		-		-		-		-
Total			731,646		2.18	$	2.12	$	1,925,599		511,824	$	1.45	$	1,679,451

GEOGRAPHIC INFORMATION (Tables)

12 Months Ended

Dec. 31, 2012

GEOGRAPHIC INFORMATION [Abstract]

Net sales by geographic area

	For the years ended
	December 31, 2012		December 31, 2011
Africa	$	2,669,140	$	2,340,635
Asia		658,831		1,784,817
Europe		54,280		57,206
North America		8,630,956		8,522,878
South America		12,314,148		4,716,775
	$	24,327,355	$	17,422,311

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2012

COMMITMENTS AND CONTINGENCIES [Abstract]

Schedule of future minimum salary commitment

2013	$	422,500
2014		300,000
2015		300,000
2016		50,000

Schedule of future minimum rental commitments

The following is a schedule of future minimum rental commitments (assuming no increases):

Years ending December 31,

2013	$	246,360
2014		82,120
	$	328,480

Customer and purchase concentration risks

The following table delineates sales the Company had to customers in excess of 10% of total sales for the periods indicated:

									Accounts
	For the years ended								Receivable As of
	December 31, 2012				December 31, 2011				December 31, 2012		December 31, 2011
	Sales		% of Sales		Sales		% of Sales
Customer 1	$	7,778,688		32	$	7,208,712		41	$	879,089		782,300
Customer 2		10,299,216		42		4,662,607		27		1,668,156		685,692
Customer 3		*		*		1,713,390		10		596		450,000

In the table above the asterisk (*) indicates that sales to the customer did not exceed 10% for the period indicated.

The following table delineates purchases the Company had with vendors in excess of 10% of total purchases for the periods indicated.

Accounts

For the years ended

Payable As of

December 31, 2012

December 31, 2011

December 31, 2012

December 31, 2011

Purchases

% of Purc.

Purchases

% of Purc.

Vendor 1

817,293

114,895

3,380

Vendor 2

778,793

76,932

23,327

In the table above the asterisk (*) indicates that purchases from the vendor did not exceed 10% for the period indicated

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References + Details

DESCRIPTION OF BUSINESS (Details)	Dec. 31, 2012
Lateral Flow Rapid HIV Tests [Member]
Product Information [Line Items]
Percentage of net product revenue to total net revenue (in hundredths)	56.00%
Products Based on Patented DPP Platform [Member]
Product Information [Line Items]
Percentage of net product revenue to total net revenue (in hundredths)	41.00%
Other Rapid Tests [Member]
Product Information [Line Items]
Percentage of net product revenue to total net revenue (in hundredths)	3.00%

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
License Agreement [Abstract]
License agreement	$ 1,000,000
Estimated economic life	10 years
Current portion of license agreement	$ 100,000	$ 100,000
Long term portion of license agreement	400,000	500,000
Revenue Recognition [Abstract]
Unrecognized customer deposits	$ 23,224	$ 0
Earnings Per Share [Abstract]
Reverse stock split conversion ratio	1-for-8
Common stock outstanding before reverse stock split (in shares)	63,967,263
Common stock outstanding after reverse stock split (in shares)	7,995,918
Summary of weighted average shares used for computation of basic and diluted earnings per share [Abstract]
Basic (in shares)	7,986,030	7,874,807
Diluted (in shares)	8,614,944	8,556,284
Summary of common share equivalent basis, used in diluted per share computations [Abstract]
1999 and 2008 Plan Stock Options (in shares)	628,914	681,477
Options and warrants excluded from computation of earnings per share (in shares)	161,464	182,343
Minimum [Member]
Fixed Assets [Abstract]
Estimated useful lives of fixed assets	3 years
Maximum [Member]
Fixed Assets [Abstract]
Estimated useful lives of fixed assets	7 years

INVENTORIES (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Inventories [Abstract]
Raw materials	$ 1,418,071	$ 1,340,177
Work in process	561,530	390,162
Finished goods	508,470	569,947
Inventories	$ 2,488,071	$ 2,300,286

FIXED ASSETS (Details) - USD ($)	12 Months Ended
FIXED ASSETS (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Summary of fixed assets [Abstract]
Fixed assets, gross	$ 3,706,022	$ 3,289,787
Less accumulated depreciation and amortization	(2,278,376)	(2,227,511)
Fixed assets, net	1,427,646	1,062,276
Depreciation expenses	423,000	338,000
Deposits on various equipment	223,584	139,790
Additional obligation relating to milestones	61,071
Machinery and Equipment [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	2,439,596	1,982,926
Furniture and Fixtures [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	287,412	221,299
Computer and Telephone Equipment [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	151,737	460,842
Leasehold Improvements [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	798,049	595,492
Automobiles [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	29,228	29,228
Assets Held under Capital Leases [Member]
Summary of fixed assets [Abstract]
Fixed assets, net	0	$ 24,000
Equipment Undergoing Validation [Member]
Summary of fixed assets [Abstract]
Fixed assets, gross	$ 323,000

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Summary of accounts payable and accrued liabilities [Abstract]
Accounts payable - suppliers	$ 1,686,431	$ 1,258,465
Accrued commissions	238,150	205,588
Accrued royalties / license fees	583,923	480,297
Accrued payroll	262,439	174,398
Accrued vacation	181,636	156,884
Accrued bonuses	155,663	284,375
Accrued expenses - other	195,681	229,493
TOTAL	$ 3,303,923	$ 2,789,500

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

DEFERRED RESEARCH AND DEVELOPMENT REVENUE (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
DEFERRED RESEARCH AND DEVELOPMENT REVENUE [Abstract]
Unearned advanced revenues	$ 0	$ 0

TERM NOTE, REVOLVING DEMAND NOTE, VEHICLE FINANCING AND LICENSE FEE PAYABLE (Details)	12 Months Ended
	Dec. 31, 2012 USD ($)	Jan. 17, 2013 USD ($)	Dec. 31, 2011
Debt Instrument [Line Items]
Number of agreements with lender	3
Security Agreement [Member]
Debt Instrument [Line Items]
Debt covenants, description	The Security Agreement contains covenants that place restrictions on the Company's operations, including covenants relating to mergers, debt restrictions, capital expenditures, tangible net worth, net profit, leverage, fixed charge coverage, employee loan restrictions, distribution restrictions (common stock and preferred stock), dividend restrictions, restrictions on lease payments to affiliates, restrictions on changes in business, asset sale restrictions, restrictions on acquisitions and intercompany transactions, restrictions on fundamental changes. The Security Agreement also requires that the Company maintain a minimum tangible net worth at all times of greater than $3,000,000 and EBITDA to CMLTD plus interest cannot be less than 1.25 to 1.00 for any fiscal year. (EBITDA is earnings before interest, taxes, depreciation and amortization; CMLTD is defined as, for any one-year period, the current scheduled principal payments required to be paid for the applicable period.).
Minimum tangible net worth	$ 3,000,000
EBITDA to CMLTD plus interest ratio	1.25
Covenant compliance	The Company was in compliance with all required financial covenants at December 31, 2012.
Vehicle Financing [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 29,000
Debt instrument, term	3 years
Periodic payment on debt	$ 849
Interest rate (in hundredths)			2.90%
Long-term Debt	0
Term Note [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 250,000
Debt instrument, term	60 months
Periodic payment on debt	$ 4,775
Interest rate (in hundredths)	5.50%
Maturity date	Jun. 30, 2015
Long-term Debt	$ 133,000
Future minimum payments, excluding interest		$ 129,000
Equipment Note [Member]
Debt Instrument [Line Items]
Debt instrument, term	60 months
Demand Note [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 250,000
Interest rate description	one-quarter percent above prime per annum
Clean-up period	30 days
Equipment Note [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 500,000
Interest rate description	one-quarter percent above prime per annum
Period after which equipment note is converted into term note	1 year

INCOME TAXES (Details) - USD ($)	12 Months Ended
INCOME TAXES (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Current [Abstract]
Federal	$ 33,054	$ 22,082
State	5,098	402
Total current provision	38,152	22,484
Deferred [Abstract]
Federal	464,005	(5,155,713)
State	7,080	0
Total deferred provision	471,085	(5,155,713)
Total provision	509,237	(5,133,229)
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 12,274,761
Net operating losses, expiration dates	between 2020 and 2028
Sustained profitable operating performance period	3 years
Valuation allowance reversed	$ 5,156,000
Current assets [Abstract]
Inventory reserves	224,694	260,665
Accrued expenses	226,740	145,426
Net current deferred asset	451,434	406,091
Noncurrent assets [Abstract]
Net operating loss carry-forwards	4,236,008	4,837,466
Research and development credit	711,444	581,576
Other Credits	97,234	0
Other	99,097	132,734
Gross noncurrent deferred tax assets	5,143,783	5,551,776
Depreciation	(199,145)	(220,578)
Noncurrent deferred tax assets	4,944,638	5,331,198
Less valuation allowances	(711,444)	(581,576)
Net noncurrent deferred tax assets	$ 4,233,194	$ 4,749,622
Summary of reconciliation of the Federal statutory rate to the effective rate applicable to income (loss) before income taxes [Abstract]
Federal income tax at statutory rates (in hundredths)	34.00%	34.00%
State income taxes, net of federal benefit (in hundredths)	0.70%	0.00%
Nondeductible expenses (in hundredths)	5.40%	6.40%
Change in valuation allowance (in hundredths)	8.90%	(514.30%)
Tax Credits (in hundredths)	(8.90%)	0.00%
Change in tax rates (in hundredths)	(5.20%)	0.00%
Other (in hundredths)	0.20%	(0.70%)
Income tax (benefit) (in hundredths)	35.10%	(474.60%)
Research and Development Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward	$ 711,000
Research and Development Tax Credit Carryforward [Member] \| Minimum [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, expiration date	Dec. 31, 2025
Research and Development Tax Credit Carryforward [Member] \| Maximum [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, expiration date	Dec. 31, 2032
Federal [Member] \| Minimum [Member]
Income Tax Contingency [Line Items]
Open tax year	2009
Federal [Member] \| Maximum [Member]
Income Tax Contingency [Line Items]
Open tax year	2011
New York state [Member] \| Minimum [Member]
Income Tax Contingency [Line Items]
Open tax year	2009
New York state [Member] \| Maximum [Member]
Income Tax Contingency [Line Items]
Open tax year	2011
2004 Change [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 5,832,516
Annual limitation	$ 150,608
Period of built-in gains	5 years
Built-in-gains of net operating losses	$ 488,207
Net operating losses, expiration dates	2018 through 2024
2006 Change [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 8,586,861
Annual limitation	$ 1,111,831
Period of built-in gains	5 years
Built-in-gains of net operating losses	$ 1,756,842
Net operating losses, expiration dates	2018 through 2028

STOCKHOLDERS' EQUITY (Details)			1 Months Ended	3 Months Ended				12 Months Ended
STOCKHOLDERS' EQUITY (Details)	Feb. 16, 2012 $ / shares shares	Apr. 26, 2011 USD ($) shares	Mar. 31, 2012 $ / shares shares	Dec. 31, 2012 shares	Sep. 30, 2012 $ / shares shares	Jun. 30, 2012 shares	Mar. 31, 2012 shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($) $ / shares shares	Dec. 19, 2012 shares	Sep. 19, 2012 shares	Jun. 19, 2012 shares	Apr. 26, 2012 $ / shares	Mar. 19, 2012 shares
Common Stock [Abstract]
Number of stock options exercised (in shares)								111,459	76,927
Exercise prices of stock option, minimum (in dollars per share) \| $ / shares								$ 1.04	$ 1.04
Exercise prices of stock option, maximum (in dollars per share) \| $ / shares								$ 1.76	$ 1.76
Common stock issued as part of consultant's compensation (in shares)				938	938	938	938
Preferred Stock [Abstract]
Preferred stock - shares authorized (in shares)				10,000,000				10,000,000	10,000,000
Preferred stock - shares outstanding (in shares)				0				0	0
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Reduced attributable expense \| $								$ 318,215	$ 189,347
Warrants [Abstract]
Warrants outstanding (in shares)				0				0	33,381
Number of warrants exercised (in shares)		513,698
Exercise price of warrants (in dollars per share) \| $ / shares									0.81				0.40
Proceeds from warrant exercises \| $		$ 205,479
Executives [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options issued to purchase of common stock (in shares)	25,392
Exercise price of stock option (in dollars per share) \| $ / shares	$ 4.00
Expiration period of stock option								5 years
Consultants [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options issued to purchase of common stock (in shares)			3,750
Exercise price of stock option (in dollars per share) \| $ / shares			$ 4.00
Options vested										938	938	938		938
Fair value of stock option \| $								$ 8,010
Reduced attributable expense \| $								$ 50
Newly Hired Vice Presidents [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options issued to purchase of common stock (in shares)					72,000
Expiration period of stock option					1 year
Number of equal annual installments with in which options are exercisable					3
New Vice Presidents [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options issued to purchase of common stock (in shares)					36,000
Exercise price of stock option (in dollars per share) \| $ / shares					$ 5.11
Other New Vice President [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options issued to purchase of common stock (in shares)					36,000
Exercise price of stock option (in dollars per share) \| $ / shares					$ 4.45
Expiration period of stock option					5 years

RIGHTS AGREEMENT (Details) - $ / shares	Mar. 08, 2010	Dec. 31, 2012	Dec. 31, 2011
RIGHTS AGREEMENT [Abstract]
Conversion basis of dividend distribution	one preferred share purchase right (a "Right") for each outstanding share of Common Stock
Common stock, par value (in dollars per share)		$ 0.01	$ 0.01
Minimum combined ownership of outstanding shares of common stock by acquiring person (in hundredths)		15.00%

EMPLOYEE STOCK OPTION PLAN (Details) - USD ($)	12 Months Ended
EMPLOYEE STOCK OPTION PLAN (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2008	Dec. 31, 1999
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options exercised under the plan (in shares)	111,459	76,927
Weighted average estimated grant-date fair value of stock options granted (in dollars per share)	$ 3.27	$ 1.76
Stock options, number of shares [Roll forward]
Exercised (in shares)	(111,459)	(76,927)
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period	$ 1,925,599
Exercisable, aggregate intrinsic value, end of period	1,679,451
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$ 294,000	$ 189,000
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 1.04	$ 1.04
Range of exercise prices, maximum (in dollars per share)	$ 1.76	$ 1.76
Stock Options Outstanding [Abstract]
Shares (in shares)			731,646
Average remaining contract life	2 years 2 months 9 days
Weighted average exercise price (in dollars per share)			$ 2.12
Aggregate intrinsic value	$ 1,925,599		$ 1,925,599
Stock Options Exercisable [Abstract]
Shares (in shares)			511,824
Weighted average exercise price (in dollars per share)			$ 1.45
Aggregate intrinsic value	$ 1,679,451		$ 1,679,451
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding under the plan (in shares)	765,903	765,903	731,646	765,903
Number of stock options exercised under the plan (in shares)	111,459
Assumptions made in calculating fair values of options [Abstract]
Expected term (in years)		3 years 9 months
Expected volatility minimum (in hundredths)	99.60%	97.11%
Expected volatility maximum (in hundredths)	115.77%	117.90%
Expected dividend yield (in hundredths)
Risk-free interest rate minimum (in hundredths)	0.33%	0.57%
Risk-free interest rate minimum (in hundredths)	0.37%	1.24%
Stock options, number of shares [Roll forward]
Outstanding, beginning of period (in shares)	765,903
Granted (in shares)	97,392
Exercised (in shares)	(111,459)
Forfeited/expired/cancelled (in shares)	(20,190)
Outstanding, end of period (in shares)	731,646	765,903
Exercisable, end of period (in shares)	511,824
Stock options, weighted average exercise price per share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 1.68
Granted (in dollars per share)	4.58
Exercised (in dollars per share)	1.08
Forfeited/expired/cancelled (in dollars per share)	3.89
Outstanding, end of period (in dollars per share)	2.23	$ 1.68
Exercisable, end of period (in dollars per share)	$ 1.45
Stock options, additional disclosure [Abstract]
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	2 years 2 months 9 days	2 years 7 months 10 days
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	2 years 2 months 9 days	2 years 7 months 10 days
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	1 year 6 months 26 days
Outstanding, aggregate intrinsic value, beginning of period	$ 1,339,693
Outstanding, aggregate intrinsic value, end of period	3,460,686	$ 1,339,693
Exercisable, aggregate intrinsic value, end of period	$ 2,438,665
Net unrecognized compensation cost			$ 305,000
Weighted average period for recognition of net unrecognized compensation cost	9 months 22 days
Total fair value of stock options vested during period	$ 144,000	149,000
Stock Options Outstanding [Abstract]
Aggregate intrinsic value	1,339,693	1,339,693	3,460,686	$ 1,339,693
Stock Options Exercisable [Abstract]
Aggregate intrinsic value	$ 2,438,665		$ 2,438,665
Stock Options [Member] \| Employees [Member]
Stock options, number of shares [Roll forward]
Granted (in shares)	97,392
Stock options, weighted average exercise price per share [Roll Forward]
Granted (in dollars per share)	$ 4.58
Stock Options [Member] \| Consultant [Member]
Stock options, number of shares [Roll forward]
Granted (in shares)	3,750
Stock options, weighted average exercise price per share [Roll Forward]
Granted (in dollars per share)	$ 4.00
Stock Options [Member] \| Minimum [Member]
Assumptions made in calculating fair values of options [Abstract]
Expected term (in years)	4 years
Stock Options [Member] \| Maximum [Member]
Assumptions made in calculating fair values of options [Abstract]
Expected term (in years)	5 years
Cost of Goods Sold [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$ 49,000	18,000
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	71,000	56,000
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$ 174,000	$ 115,000
1999 Stock Option Plan [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)			375,000			187,500
Number of stock options outstanding under the plan (in shares)	135,191		135,191
Maximum period of stock option issuance after adoption of SOP	10 years
Stock options, number of shares [Roll forward]
Outstanding, end of period (in shares)	135,191
2008 Stock Incentive Plan [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)				750,000	625,000
Increase in number of shares authorized (in shares)	125,000
Number of stock options outstanding under the plan (in shares)	596,455		596,455
Number of stock options exercised under the plan (in shares)	84,584
Options still available to be issued (in shares)			68,961
Stock options, number of shares [Roll forward]
Exercised (in shares)	(84,584)
Outstanding, end of period (in shares)	596,455
0 to 1.50 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period	$ 1,466,159
Exercisable, aggregate intrinsic value, end of period	$ 1,396,971
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 0
Range of exercise prices, maximum (in dollars per share)	$ 1.50
Stock Options Outstanding [Abstract]
Shares (in shares)			397,333
Average remaining contract life	1 year 3 months 15 days
Weighted average exercise price (in dollars per share)			$ 1.04
Aggregate intrinsic value	$ 1,466,159		$ 1,466,159
Stock Options Exercisable [Abstract]
Shares (in shares)			378,583
Weighted average exercise price (in dollars per share)			$ 1.04
Aggregate intrinsic value	1,396,971		$ 1,396,971
1.5001 to 2 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period	123,080
Exercisable, aggregate intrinsic value, end of period	$ 123,080
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 1.5001
Range of exercise prices, maximum (in dollars per share)	$ 2
Stock Options Outstanding [Abstract]
Shares (in shares)			41,441
Average remaining contract life	1 month 17 days
Weighted average exercise price (in dollars per share)			$ 1.76
Aggregate intrinsic value	$ 123,080		$ 123,080
Stock Options Exercisable [Abstract]
Shares (in shares)			41,441
Weighted average exercise price (in dollars per share)			$ 1.76
Aggregate intrinsic value	123,080		$ 123,080
2.0001 to 3.5 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period	277,318
Exercisable, aggregate intrinsic value, end of period	$ 136,625
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 2.0001
Range of exercise prices, maximum (in dollars per share)	$ 3.5
Stock Options Outstanding [Abstract]
Shares (in shares)			131,250
Average remaining contract life	3 years 3 months 11 days
Weighted average exercise price (in dollars per share)			$ 2.62
Aggregate intrinsic value	$ 277,318		$ 277,318
Stock Options Exercisable [Abstract]
Shares (in shares)			62,500
Weighted average exercise price (in dollars per share)			$ 2.54
Aggregate intrinsic value	136,625		$ 136,625
3.5001 to 4.5 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period	59,042
Exercisable, aggregate intrinsic value, end of period	$ 22,775
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 3.5001
Range of exercise prices, maximum (in dollars per share)	$ 4.5
Stock Options Outstanding [Abstract]
Shares (in shares)			125,622
Average remaining contract life	3 years 10 months 2 days
Weighted average exercise price (in dollars per share)			$ 4.26
Aggregate intrinsic value	$ 59,042		$ 59,042
Stock Options Exercisable [Abstract]
Shares (in shares)			29,300
Weighted average exercise price (in dollars per share)			$ 3.95
Aggregate intrinsic value	22,775		$ 22,775
4.50001 to 8 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period	0
Exercisable, aggregate intrinsic value, end of period	$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)	$ 4.50001
Range of exercise prices, maximum (in dollars per share)	$ 8
Stock Options Outstanding [Abstract]
Shares (in shares)			36,000
Average remaining contract life	4 years 7 months 6 days
Weighted average exercise price (in dollars per share)			$ 5.11
Aggregate intrinsic value	$ 0		$ 0
Stock Options Exercisable [Abstract]
Shares (in shares)			0
Weighted average exercise price (in dollars per share)			$ 0
Aggregate intrinsic value	$ 0		$ 0

GEOGRAPHIC INFORMATION (Details) - USD ($)	12 Months Ended
GEOGRAPHIC INFORMATION (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 24,327,355	$ 17,422,311
Africa [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	2,669,140	2,340,635
Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	658,831	1,784,817
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	54,280	57,206
North America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	8,630,956	8,522,878
South America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	12,314,148	4,716,775
Uganda [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	106,000
Nigeria [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	298,000
Middle East [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	1,220,000
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	7,720,000	7,210,000
Brazil [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 10,300,000	$ 4,660,000

COMMITMENTS AND CONTINGENCIES (Details)

12 Months Ended

Dec. 31, 2012

USD ($)

Dec. 31, 2011

USD ($)

Employment Contracts [Abstract]

Number of key employees with whom Company has employment contracts

Aggregate annual salaries of employment contracts

$ 590,000

Future minimum salary commitments [Abstract]

422,500

300,000

300,000

$ 50,000

Pension Plan [Abstract]

Percentage of employer's matching contribution (in hundredths)

40.00%

Maximum employee contribution subject to employer matching contribution (in hundredths)

5.00%

Maximum employer matching contribution (in hundredths)

2.00%

$ 64,604

$ 61,628

Obligations Under Operating Leases [Abstract]

Monthly rent

$ 20,530

Lease expiration date

Apr. 30, 2014

Percentage of monthly rent increase in year three through five (in hundredths)

2.50%

Schedule of future minimum rental commitments [Abstract]

$ 246,360

82,120

328,480

231,700

177,200

Economic Dependency [Abstract]

Sales

24,327,355

17,422,311

Accounts Receivable

4,821,357

2,998,449

Accounts Payable

$ 1,686,431

1,258,465

Customer Concentration Risk [Member]

Economic Dependency [Abstract]

Concentration risk percentage, minimum (in hundredths)

10.00%

Customer Concentration Risk [Member] | Customer 1 [Member]

Economic Dependency [Abstract]

Accounts Receivable

$ 879,089

782,300

Customer Concentration Risk [Member] | Customer 2 [Member]

Economic Dependency [Abstract]

Accounts Receivable

1,668,156

685,692

Customer Concentration Risk [Member] | Customer 3 [Member]

Economic Dependency [Abstract]

Accounts Receivable

$ 596

450,000

Supplier Concentration Risk [Member]

Economic Dependency [Abstract]

Concentration risk percentage, minimum (in hundredths)

10.00%

Supplier Concentration Risk [Member] | Vendor 1 [Member]

Economic Dependency [Abstract]

Accounts Payable

$ 114,892

Supplier Concentration Risk [Member] | Vendor 2 [Member]

Economic Dependency [Abstract]

Accounts Payable

76,932

Sales [Member] | Customer Concentration Risk [Member] | Customer 1 [Member]

Economic Dependency [Abstract]

Sales

$ 7,778,688

$ 7,208,712

Concentration risk, percentage (in hundredths)

32.00%

41.00%

Sales [Member] | Customer Concentration Risk [Member] | Customer 2 [Member]

Economic Dependency [Abstract]

Sales

$ 10,299,216

$ 4,662,607

Concentration risk, percentage (in hundredths)

42.00%

27.00%

Sales [Member] | Customer Concentration Risk [Member] | Customer 3 [Member]

Economic Dependency [Abstract]

Sales

^[1]

$ 1,713,390

Concentration risk, percentage (in hundredths)

^[1]

10.00%

Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 1 [Member]

Economic Dependency [Abstract]

Concentration risk, percentage (in hundredths)

13.00%

^[2]

Purchases

$ 817,293

^[2]

Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 2 [Member]

Economic Dependency [Abstract]

Concentration risk, percentage (in hundredths)

12.00%

^[2]

Purchases

$ 778,793

^[2]

[1]	In the table above the asterisk (*) indicates that sales to the customer did not exceed 10% for the period indicated.
[2]	In the table above the asterisk (*) indicates that purchases from the vendor did not exceed 10% for the period indicated

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS (Details)	1 Months Ended			12 Months Ended
	Jul. 31, 2012 USD ($)	Apr. 30, 2011 USD ($)	Jun. 30, 2009 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2008
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues from research and milestones				$ 1,283,240	$ 1,825,403
Research and development expenses, excluding regulatory and QTDP				3,100,000	3,100,000
Fiocruz [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues from research and milestones				$ 0	505,000
Number of agreements signed by entity						4
DPP? Leishmaniasis [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Amount of milestone events triggered					305,000
Syphilis Screen [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Amount of milestone events triggered					100,000
Leptospirosis [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Amount of milestone events triggered					100,000
Development of Test for Leptospirosis [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Grant received			$ 3,000,000
Term of grant				3 years
Revenue earned from grant				$ 270,000	690,000
Revenue from grants from inception				2,756,000
Amount paid to subcontractors				$ 898,000
Development of Test for Tuberculosis [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Grant received		$ 2,400,000
Term of grant				3 years
Revenue earned from grant				$ 682,000	$ 350,000
Revenue from grants from inception				1,377,000
Amount paid to subcontractors				345,000
(DPP?) Technology [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum amount of development agreement	$ 480,000
Period in which development activity is to be completed	9 months
Research and development payments received under the agreement				$ 278,000